| Name | Cloperastine fendizoate |
| Description | Cloperastine fendizoate (Hustazol) inhibits the hERG K+ currents in a concentration-dependent manner (IC50: 27 nM). |
| In vitro | Among the antitussive agents, Cloperastine, which possesses antitussive and antiedemic activity, also relaxes the bronchial musculature. Cloperastine is also endowed with an antihistaminic and papaverine-like activity similar to codeine but without its narcotic effects [2]. |
| In vivo | In anesthetized guinea pigs, a therapeutic dose (1 mg/kg) of Cloperastine extended the QT interval and monophasic action potential duration, without altering the PR interval or QRS width [1]. When administered intraperitoneally, Cloperastine hydrochloride exhibits relatively low acute toxicity in rats and mice. As Cloperastine fendizoate, its oral administration demonstrates minimal toxicity, with LD50 values exceeding 1000 and 2000 mg/kg in rats and mice, respectively [2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 8 mg/mL (12.34 mM), Sonication is recommended.
|
| Keywords | K+ currents | hERG Potassium Channel | Cloperastine fendizoate |
| Inhibitors Related | Minoxidil sulfate | Tannic acid | Osimertinib | Hydrochlorothiazide | Lapatinib | Erlotinib | Neratinib | Ursodeoxycholic acid | Afatinib | Gefitinib | Chlorzoxazone | Indapamide |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Tyrosine Kinase Inhibitor Library | Kinase Inhibitor Library | JAK-STAT Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Cancer Approved Drug Library | FDA-Approved Kinase Inhibitor Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library |
United States
